CN113662919B - Stable cefixime tablet and preparation method thereof - Google Patents
Stable cefixime tablet and preparation method thereof Download PDFInfo
- Publication number
- CN113662919B CN113662919B CN202111119913.1A CN202111119913A CN113662919B CN 113662919 B CN113662919 B CN 113662919B CN 202111119913 A CN202111119913 A CN 202111119913A CN 113662919 B CN113662919 B CN 113662919B
- Authority
- CN
- China
- Prior art keywords
- cefixime
- tablet
- stable
- tablets
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Abstract
The invention provides a preparation method of a stable cefixime tablet, which comprises the following steps: carrying out wet granulation and drying on the cefixime bulk drug, adding other materials, mixing and tabletting to obtain a stable cefixime tablet; the particle size d of the cefixime bulk drug 90 In the range of 20 to 90 μm. The tablet prepared by the method provided by the invention can effectively solve the sticking problem in the pressing process of the cefixime tablet, and improve the chemical stability and dissolution rate of cefixime in the preparation.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a stable cefixime tablet and a preparation method thereof.
Background
Cefixime trihydrate, (6R, 7R) -7- [ (Z) -2- (2-amino-4-thiazolyl) -2- (carboxymethoxyimino) acetamido]8-oxo-3-ethene-5-thia-1-azabicyclo [4.2.0 ]]Xin 2-ene-2-carboxylic acid trihydrate having the molecular formula C 16 H 15 N 5 O 7 S 2 ·3H 2 O, molecular weight 507.50. The chemical structural formula of cefixime is as follows:
the three crystal waters contained in cefixime are of great importance for its chemical stability, and therefore, during the formulation process, it is necessary to prevent the loss of crystal water to maintain the chemical stability of cefixime trihydrate.
The cefixime tablets on the market at present are basically prepared by adopting a powder direct compression process or a wet granulation process: (1) The powder direct-pressing process needs to control the particle size of the raw material medicine in a larger range so as to solve the problem of material fluidity and avoid material layering in the tabletting process. The crystal structure of cefixime is easy to be damaged in the tabletting process of the powder direct pressing process, thereby being not beneficial to the chemical stability of cefixime; the powder is also easy to have sticking phenomenon in the direct compression, so that the tabletting process is not smooth or the humidity needs to be strictly controlled, so that the tablet production process is not smooth; (2) The wet granulation process is more unfavorable for the production of cefixime tablets, because beta-lactam rings on the cefixime structure are easy to hydrolyze and open the rings under the conditions of high temperature and high humidity, the cefixime is oxidized or degraded, and the stability of the preparation product is poor, thus being unfavorable for long-term storage.
Disclosure of Invention
In view of the limitation of the existing production process of cefixime tablets, the invention aims to provide a stable cefixime tablet and a preparation method thereof.
The invention provides a preparation method of a stable cefixime tablet, which comprises the following steps:
mixing and granulating the cefixime bulk drug and an adhesive, and drying to obtain granules;
mixing the granules and auxiliary materials, and pressing into tablets to obtain stable cefixime tablets;
the particle size d of the cefixime bulk drug 90 20 to 90 mu m.
Preferably, the auxiliary materials include: fillers, glidants, and lubricants.
Preferably, the mass content of the cefixime bulk drug in the stable cefixime tablet is 10-70%; the mass content of the adhesive in the stable cefixime tablet is 0.3-1.5%; the mass content of the filler in the stable cefixime tablet is 25-85%; the mass content of the glidant in the stable cefixime tablet is 0.5-5.0%; the mass content of the lubricant in the stable cefixime tablet is 0.3-4.0%.
Preferably, the binder is selected from at least one of methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, povidone, starch, and gelatin.
Preferably, the filler is selected from at least one of microcrystalline cellulose, pregelatinized starch, lactose, sucrose, and dibasic calcium phosphate.
Preferably, the glidant is selected from at least one of talc and colloidal silicon dioxide.
Preferably, the lubricant is selected from at least one of magnesium stearate, calcium stearate, hydrogenated vegetable oil, and polyethylene glycol.
Preferably, the auxiliary materials further include: a disintegrating agent.
Preferably, the disintegrant is selected from at least one of sodium carboxymethyl starch, croscarmellose sodium, low substituted hydroxypropyl cellulose, and crospovidone.
The invention provides a stable cefixime tablet prepared by the method in the technical scheme.
The stable preparation method of cefixime tablets provided by the invention has the advantages of good product quality stability and good material fluidity in the production process, and solves the defects of tablet sticking and poor product chemical stability in the prior art.
Drawings
FIG. 1 is a dissolution profile of tablets prepared in examples 1 and 4 of the present invention;
fig. 2 is a particle size distribution diagram of cefixime bulk drug used in example 2 of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a preparation method of a stable cefixime tablet, which comprises the following steps:
carrying out wet granulation on the cefixime raw material medicine by using an adhesive, and drying to obtain medicine-containing granules;
mixing the drug-containing granules with other auxiliary materials and then pressing into tablets to obtain stable cefixime tablets;
the particle size d of the cefixime bulk drug 90 20 to 90 mu m.
The invention provides a preparation method of a stable cefixime tablet, which preferably comprises the following steps:
mixing and granulating the cefixime bulk drug and an adhesive to obtain granules;
mixing the granules and auxiliary materials, and pressing into tablets to obtain stable cefixime tablets;
the particle size d of the cefixime bulk drug 90 20 to 90 mu m.
In the invention, the cefixime bulk drug contains cefixime trihydrate (6R, 7R) -7- [ (Z) -2- (2-amino-4-thiazolyl) -2- (carboxymethoxyimino) acetamido)]-8-oxo-3-ethene-5-thia-1-azabicyclo [4.2.0]Oct-2-ene-2-carboxylic acid trihydrate having the molecular formula C 16 H 15 N 5 O 7 S 2 3H2O, molecular weight 507.50.
In the invention, the particle size d of the cefixime bulk drug 90 Is 20 to 90 μm, preferably 20 to 50 μm, and more preferably 30 to 40 μm.
In the invention, the mass content of the cefixime bulk drug in the stable cefixime tablet is preferably 10-70%, more preferably 20-50%, and more preferably 30-50%.
In the present invention, the binder is preferably selected from at least one selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, povidone, starch, and gelatin.
In the present invention, the mass content of the binding agent in the stable cefixime tablet is preferably 0.3% to 1.5%, more preferably 0.5% to 1.2%.
In the present invention, the method of granulating preferably comprises:
mixing cefixime bulk drug and adhesive solution, granulating, drying, and finishing granules to obtain granules.
In the present invention, the binder solution is preferably an aqueous binder solution; the mass concentration of the binder solution is preferably 2% to 14%, more preferably 5% to 10%.
In the invention, the granulation is preferably carried out in a high-efficiency wet granulator, the cefixime bulk drug is placed in the high-efficiency wet granulator, and the binder solution is atomized and sprayed under mixed shear to carry out the granulation.
In the present invention, the drying temperature is preferably 30 to 50 ℃, more preferably 35 to 45 ℃, and most preferably 40 ℃; the drying mode is preferably oven drying.
In the present invention, the size of the whole grain is preferably 30 to 50 mesh, more preferably 35 to 45 mesh, and most preferably 40 mesh.
In the present invention, the auxiliary materials preferably include: fillers, glidants, and lubricants.
In the present invention, the filler is preferably at least one selected from the group consisting of microcrystalline cellulose, pregelatinized starch, lactose, sucrose and calcium hydrogen phosphate; the fluidity of the filler meets the requirements of a powder direct compression process.
In the present invention, the mass content of the filler in the stable cefixime tablet is preferably 25% to 85%, more preferably 30% to 80%.
In the present invention, the glidant is preferably at least one selected from talc and colloidal silicon dioxide.
In the invention, the mass content of the glidant in the stable cefixime tablet is preferably 0.5-5.0%.
In the present invention, the lubricant is preferably at least one selected from the group consisting of magnesium stearate, calcium stearate, hydrogenated vegetable oil, and polyethylene glycol.
In the present invention, the mass content of the lubricant in the stable cefixime tablet is preferably 0.3-4.0%.
In the present invention, the auxiliary materials preferably further include: a disintegrating agent.
In the present invention, the disintegrant is preferably at least one selected from the group consisting of sodium carboxymethyl starch, croscarmellose sodium, low substituted hydroxypropyl cellulose and crospovidone.
In the present invention, the mass content of the disintegrant in the stable cefixime tablet is preferably 2% to 8%, more preferably 3% to 6%.
In the present invention, the tabletting method is preferably rotary tabletting; the rotation speed during the tabletting process is preferably 10rpm to 35rpm.
In the invention, when the specification of cefixime in the tabletting process is 0.1 g/tablet, the hardness of the tabletting is preferably controlled to be 4 kg-7 kg; when the cefixime specification is 50 mg/tablet, the hardness of the tablet is preferably controlled to be 3 kg-6 kg.
The invention also provides a stable cefixime tablet prepared by the method in the technical scheme.
The preparation method of the cefixime tablets provided by the invention is different from the traditional method. Generally, cefixime is not suitable for wet granulation, because wet granulation easily causes the hydrolysis and ring opening of beta-lactam ring on the cefixime structure under high temperature and high humidity conditions, and cefixime generates degradation products to gradually lose efficacy. However, the method provided by the invention is different from the traditional wet granulation process, the traditional wet granulation process is to granulate, dry and totally mix and tablet the mixture after mixing the raw materials and the auxiliary materials, and the invention only granulates and dries the raw materials and then mixes the raw materials and the auxiliary materials such as the filling agent and the like and then tablets.
In addition, the current production technology of cefixime tablets mainly is the direct preforming of powder, is about to directly preforming after the raw and auxiliary materials mixes, and the purpose is to avoid the moisture and the dry process of being heated in the wet granulation process to guarantee cefixime's chemical stability. However, the direct powder compression process has disadvantages in that: (1) Cefixime tablets are easy to stick and impact, in order to ensure that the direct tablet pressing process of powder can be smoothly carried out, the relative humidity of the environment is usually controlled to be below 55%, preferably below 40%, and the harsh tablet pressing conditions are not easy to realize, so that the comfort of workers is reduced due to too low air humidity; (2) The direct powder compression also easily causes powder layering in the tablet compression process, thereby influencing the weight difference and the content uniformity of the tablets; (3) The powder direct pressing process requires that the particle size of the bulk drug is larger, and the crystal structure of cefixime is easily damaged due to pressure bearing in the pressing process, so that the chemical stability of cefixime in the prepared tablet is deteriorated.
The invention adopts a proper adhesive to carry out wet granulation on the raw material on the basis of controlling the particle size of the cefixime raw material, and then the cefixime raw material is mixed with other auxiliary materials and tabletted. Surprisingly, the invention not only solves the sticking problem in the process of tabletting cefixime, but also obviously improves the chemical stability of cefixime, and simultaneously improves the dissolution rate of the tablet because of adopting the raw material medicine with fine particle size.
The present invention will be described in further detail by way of examples, but it should be noted that the examples are only for the purpose of better understanding of the present invention, and are not to be construed as limiting the claims.
The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The term "d" is explained herein 90 "means the particle size corresponding to 90% of the cumulative particle size distribution of a sample," d 50 "refers to the particle size corresponding to the cumulative particle size distribution of 50% for a sample," d 10 "means the particle size corresponding to the cumulative particle size distribution of 10% for a sample.
The particle sizes in the embodiments of the present invention are all measured by a laser particle analyzer, the particle sizes of samples measured by the laser particle analyzer are divided into a wet method (the samples are dispersed in a suitable liquid medium) and a dry method (the samples are dispersed in a gas and kept in a dry state), and the particle sizes in the embodiments of the present invention are all measured by the dry method.
Comparative example 1
The tablets were prepared using wet granulation according to the raw materials and dosages in table 1:
dissolving hydroxypropyl cellulose in a proper amount of purified water to prepare an aqueous solution with the concentration of 7.4 percent (g/g) as a binder solution;
placing cefixime, microcrystalline cellulose, anhydrous lactose, pregelatinized starch and carboxymethyl starch sodium in a high-efficiency wet granulator, uniformly mixing, and spraying the adhesive solution into the granulator for granulation;
drying in a forced air oven at 40 deg.C; granulating with 40 mesh sieve to obtain dry granules;
mixing the dry granules with talcum powder and magnesium stearate, tabletting (rotary tabletting, the rotating speed is 10-30 rpm), controlling the tablet weight to be 267mg and the hardness to be 4-7 kg, and obtaining tablets; the tablets are blister-packaged.
Comparative example 2
The tablets were prepared according to the raw materials and amounts in table 1 using a powder direct compression process:
putting all the materials into a three-dimensional mixer, and uniformly mixing to obtain a mixture;
mixing the talcum powder and the magnesium stearate, and tabletting to obtain tablets, wherein the weight of the tablets is 267mg, and the hardness is 4 kg-7 kg; the tablets are blister-packaged.
Table 1 formulations for preparing tablets of comparative example 1 and comparative example 2
The samples prepared in comparative examples 1 and 2 were left at 40 ℃ for 30 days, sampled at 0 days, 5 days, 10 days and 30 days, respectively, and their chemical stability was examined, and the content of impurities was measured by HPLC, and the results are shown in Table 2:
table 2 chemical stability of tablets prepared in comparative example 1 and comparative example 2
The results show that although the direct powder compression process can achieve better chemical stability than the wet granulation process, impurity control is still less than ideal; and the phenomena of large difference of tablet weight and sticking during the tabletting process also exist.
Examples 1 to 4
Tablets were prepared according to the raw material ingredients and amounts in table 3:
dissolving hydroxypropyl methylcellulose or hydroxypropyl cellulose in appropriate amount of purified water to obtain adhesive with concentration of 7.41% (g/g);
placing cefixime in an efficient wet granulator, mixing, shearing, atomizing, spraying an adhesive, and granulating;
drying by a forced air oven at 40 ℃; finishing granules by a 40-mesh screen to obtain granules;
placing the materials in a three-dimensional mixer, adding the rest materials, and mixing uniformly to obtain a mixture;
tabletting the mixture (rotary tabletting at a rotation speed of 10-30 rpm) to control the hardness to be 4-7 kg, and controlling the tablet weights of example 1, example 2, example 3 and example 4 to be 266mg, 220mg, 233mg and 234mg in sequence to obtain tablets;
blister packaging said tablets.
Table 3 formulations for preparing tablets of examples 1 to 4
In table 3, cefixime is used as a raw material drug, hypromellose and hydroxypropyl cellulose are used as adhesives, microcrystalline cellulose, lactose, pregelatinized starch and calcium hydrogen phosphate are used as fillers, carboxymethyl starch sodium and low-substituted hydroxypropyl cellulose are used as disintegrants, talcum powder and colloidal silicon dioxide are used as glidants, and magnesium stearate and hydrogenated vegetable oil are used as lubricants.
The samples obtained in example 1, example 2, example 3 and example 4 were placed at 40 ℃ for 30 days, respectively, and sampled at 0 day, 5 days, 10 days and 30 days, respectively, to examine their chemical stability, and the results are shown in Table 4:
table 4 chemical stability of tablets prepared in examples 1 to 4
The result shows that better chemical stability can be obtained only by carrying out wet granulation process tabletting on the bulk drug (the method provided by the invention), and the chemical stability of the tablet is gradually improved along with the reduction of the particle size of the bulk drug; and the raw material medicines are granulated by a wet method, so that the sticking phenomenon in the tabletting process is improved, and the tablet weight difference is reduced.
The dissolution curves of examples 1 and 4 were measured by the paddle method using a hydrochloric acid solution of ph1.2 as a dissolution medium, and the results are shown in fig. 1, which indicates that the smaller the particle size of the drug substance, the faster the dissolution.
From the above examples, it can be seen that the present invention uses a suitable adhesive to perform wet granulation on the raw material based on controlling the particle size of the cefixime raw material, and then mixes the raw material with other auxiliary materials for tabletting. Surprisingly, the invention not only solves the sticking problem in the process of tabletting cefixime, but also obviously improves the chemical stability of cefixime, and simultaneously improves the dissolution rate of the tablet because of adopting the raw material medicine with fine particle size.
While the invention has been described and illustrated with reference to specific embodiments thereof, such description and illustration are not intended to limit the invention. It will be clearly understood by those skilled in the art that various changes in form and details may be made therein without departing from the true spirit and scope of the invention as defined by the appended claims, to adapt a particular situation, material, composition of matter, substance, method or process to the objective, spirit and scope of this application. All such modifications are intended to be within the scope of the claims appended hereto. Although the methods disclosed herein have been described with reference to particular operations performed in a particular order, it should be understood that these operations may be combined, sub-divided, or reordered to form equivalent methods without departing from the teachings of the present disclosure. Accordingly, unless specifically indicated herein, the order and grouping of the operations is not a limitation of the present application.
Claims (9)
1. A process for the preparation of a stable cefixime tablet comprising:
carrying out wet granulation on the cefixime bulk drug by using an adhesive, and drying to obtain drug-containing granules;
mixing the drug-containing granules with other auxiliary materials and then pressing into tablets to obtain stable cefixime tablets;
the particle diameter d of the cefixime crude drug 90 20 to 90 mu m.
2. The method of claim 1, wherein the adjunct comprises: fillers, glidants, and lubricants.
3. The method of claim 1, wherein the binder is selected from at least one of methylcellulose, hydroxypropyl cellulose, povidone, starch, and gelatin.
4. The method of claim 2, wherein the filler is selected from at least one of microcrystalline cellulose, pregelatinized starch, lactose, sucrose, and dibasic calcium phosphate.
5. The method of claim 2, wherein the glidant is selected from at least one of talc and colloidal silicon dioxide.
6. The method of claim 2, wherein the lubricant is selected from at least one of magnesium stearate, calcium stearate, hydrogenated vegetable oil, and polyethylene glycol.
7. The method of claim 2, wherein the adjunct further comprises: a disintegrating agent.
8. The method according to claim 7, wherein the disintegrant is selected from at least one of sodium carboxymethyl starch, croscarmellose sodium, low substituted hydroxypropyl cellulose, and crospovidone.
9. A stable cefixime tablet prepared by the process of claim 1.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111119913.1A CN113662919B (en) | 2021-09-18 | 2021-09-18 | Stable cefixime tablet and preparation method thereof |
| PCT/CN2021/136038 WO2023040075A1 (en) | 2021-09-18 | 2021-12-07 | Stable cefixime tablet and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111119913.1A CN113662919B (en) | 2021-09-18 | 2021-09-18 | Stable cefixime tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113662919A CN113662919A (en) | 2021-11-19 |
| CN113662919B true CN113662919B (en) | 2022-10-11 |
Family
ID=78549991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111119913.1A Active CN113662919B (en) | 2021-09-18 | 2021-09-18 | Stable cefixime tablet and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113662919B (en) |
| WO (1) | WO2023040075A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662919B (en) * | 2021-09-18 | 2022-10-11 | 海南鑫开源医药科技有限公司 | Stable cefixime tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670536A (en) * | 2012-06-08 | 2012-09-19 | 上海新亚药业有限公司 | Method for preparing cefixime dispersible tablets |
| CN103479587A (en) * | 2013-09-06 | 2014-01-01 | 海南葫芦娃制药有限公司 | Cefixime dispersible tablets and preparation method thereof |
| CN112076172A (en) * | 2020-10-20 | 2020-12-15 | 扬州中宝药业股份有限公司 | Sulcardine sulfate tablet and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107703A1 (en) * | 2004-05-10 | 2005-11-17 | Lupin Ltd. | Novel pharmaceutical formulation of cefixime for enhanced bioavailability |
| CN101480397B (en) * | 2008-01-07 | 2012-09-19 | 上官清 | Cefixime orally disintegrating tablet and preparation method thereof |
| CN101889987B (en) * | 2009-11-16 | 2013-12-04 | 江苏亚邦强生药业有限公司 | Method for preparing novel cefixime tablets and cefixime capsules |
| CN113662919B (en) * | 2021-09-18 | 2022-10-11 | 海南鑫开源医药科技有限公司 | Stable cefixime tablet and preparation method thereof |
-
2021
- 2021-09-18 CN CN202111119913.1A patent/CN113662919B/en active Active
- 2021-12-07 WO PCT/CN2021/136038 patent/WO2023040075A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670536A (en) * | 2012-06-08 | 2012-09-19 | 上海新亚药业有限公司 | Method for preparing cefixime dispersible tablets |
| CN103479587A (en) * | 2013-09-06 | 2014-01-01 | 海南葫芦娃制药有限公司 | Cefixime dispersible tablets and preparation method thereof |
| CN112076172A (en) * | 2020-10-20 | 2020-12-15 | 扬州中宝药业股份有限公司 | Sulcardine sulfate tablet and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| DESIGN AND CHARACTERIZATION OF SUSTAINED RELEASE MINI-TABLETS OF CEFIXIME TRIHYDRATE;Shravan Kumar Gunti等;《International Journal of Pharmacy and Biological Sciences》;20040331;第4卷(第1期);第79-88页 * |
| 头孢克肟胶囊生产工艺探讨;周福生;《海峡药学》;20081231;第20卷(第6期);第33-35页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023040075A1 (en) | 2023-03-23 |
| CN113662919A (en) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3981400A1 (en) | Oral capsule and preparation method therefor | |
| CN104840960A (en) | Antidiabetic pharmaceutical composition and preparation method thereof | |
| CN112220770B (en) | Pharmaceutical composition of selepag and preparation method thereof | |
| CN113662919B (en) | Stable cefixime tablet and preparation method thereof | |
| EP3087989B1 (en) | Solid preparations comprising tofogliflozin and method for producing the same | |
| CN109875972A (en) | A kind of olmesartan medoxomil/amlodipinepharmaceutical pharmaceutical composition | |
| CN103145733B (en) | Amoxicillin compound and pharmaceutical composition of amoxicillin compound and potassium clavulanate | |
| CN110769825B (en) | Pharmaceutical composition containing quinoline derivative | |
| CN110123770A (en) | A kind of Eliquis pharmaceutical composition and preparation method thereof | |
| KR20200144432A (en) | Preparation method of tablet containing dapagliflozin ansolvate and tablet containing dapagliflozin ansolvate prepared by the same | |
| CN106176655B (en) | Penicillin V potassium tablet and preparation process thereof | |
| CN113057944B (en) | Preparation method of tablets with improved performance | |
| CN111377947B (en) | Amoxicillin trihydrate pharmaceutical composition with low water activity and preparation method thereof | |
| CN104666263B (en) | A kind of tablet containing Levetiracetam and preparation method thereof | |
| CN112826806A (en) | Preparation method of valsartan tablets and valsartan tablets | |
| CN112641750A (en) | Paroxetine hydrochloride tablet and preparation method thereof | |
| CN107405342A (en) | A kind of solid composite medicament containing diamine derivative or its salt | |
| CN113143878A (en) | Olanzapine composition and preparation method thereof | |
| CN112546018A (en) | Cefaclor capsule and preparation method thereof | |
| CN111346064A (en) | Rivaroxaban tablet and preparation method thereof | |
| CN112263569B (en) | Amoxicillin capsule and preparation method thereof | |
| CN110693884A (en) | Compound preparation valsartan amlodipine tablet and preparation method thereof | |
| CN114652688B (en) | Montelukast sodium chewable tablet and preparation method thereof | |
| KR20210015788A (en) | Rapid release drug formulation of anticoagulant and method for manufacturing same | |
| CN108514550A (en) | Solid drugs and preparation method thereof containing Abiraterone acetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A stable cefixime tablet and its preparation method Effective date of registration: 20221201 Granted publication date: 20221011 Pledgee: Haikou Rural Commercial Bank Co.,Ltd. Hongchenghu Sub branch Pledgor: Hainan xinkaiyuan Pharmaceutical Technology Co.,Ltd. Registration number: Y2022980024454 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |